Paramount’s CEO Has Been Asked to Testify The Senate’s Antitrust Subcommittee

The proposed $111 billion Paramount-Warner Bros. Discovery merger is facing increased congressional scrutiny, with Sen. Cory Booker inviting David Ellison to testify at a Wednesday antitrust hearing. Lawmakers and more than 1,000 writers, actors, and directors are warning the deal could reduce competition, shrink independent production opportunities, and pressure jobs across Hollywood. Paramount argues the transaction would boost content investment and distribution, but regulatory and stakeholder resistance remains a key overhang.

Analysis

This is less about whether the deal is ultimately approved and more about how much friction gets inserted into the path to close. For WBD, that matters because every incremental month of review raises the probability of financing slippage, remedy concessions, and operational distraction; in media M&A, process risk often becomes valuation risk before the headline outcome changes. The market is likely underpricing how much congressional theater can harden the FTC/DOJ posture, especially when labor and creative-ecosystem arguments give regulators a politically durable frame.

The second-order loser is the independent production layer: if a combined platform rationalizes greenlighting, mid-tier producers and talent agencies lose negotiation leverage first, then volume. That usually benefits the largest surviving content buyers only after a lag, because near-term they trade lower input costs for weaker slate diversity and higher antitrust scrutiny. Competitively, the bigger strategic beneficiary may be tech-native streamers and the remaining standalone studios, which can position themselves as cleaner partners for creators and distributors while WBD becomes synonymous with regulatory overhang.

The main contrarian point is that the market may be focused too much on headline antitrust risk and not enough on bargaining chips. Congressional pressure can accelerate side agreements around domestic production, licensing, and labor protections that reduce the odds of a hard block while still preserving strategic optionality. If management credibly offers concessions, the stock reaction could invert quickly over 1-3 months because the overhang is more about uncertainty duration than outright deal denial.

In the near term, the asymmetry is still negative for WBD: a small number of bad procedural steps can extend the timeline materially, while a clean hearing only removes one hurdle. The setup favors event-driven volatility rather than a one-way move, so options may be more efficient than outright equity if the goal is to express regulatory risk without taking full directional exposure.

Key Decisions for Investors

• Short WBD common into the hearing window; use a 2-6 week horizon and cover on any credible concession package or explicit timetable clarity. Risk/reward favors a modest short because downside accelerates if the process drifts, while upside is capped unless approval odds improve materially.
• Buy WBD near-dated put spreads to express event risk with defined premium outlay; target strikes around 5-10% below spot and duration through the next regulatory milestone. This is the cleaner way to capture a volatility spike if lawmakers broaden the narrative from competition to jobs and domestic production.
• Pair long NFLX / short WBD over 1-3 months as a cleaner content-platform expression. If antitrust friction slows consolidation, standalone scale premium should accrue to the highest-quality streamer rather than to a merger candidate facing policy drag.
• If already long WBD, hedge with upside calls only if the thesis is that negotiated remedies will emerge; otherwise trim into strength ahead of the hearing. The key risk is not a total deal failure but a prolonged review that compresses multiples via uncertainty.
• Watch for a shift into labor-friendly or California-production incentive language; if that appears, reduce bearish exposure because it would signal regulators are moving toward conditional approval rather than obstruction.